DiaMedica updates on ReMEDy2 trial, starts preeclampsia study, extends cash to Q3 2026

DiaMedica Therapeutics Inc.

ReMEDy2 AIS interim analysis enrollment (n=144) targeted for Q1 2025; 15 top U.S. centers prioritized.
Phase 2 preeclampsia trial begins Q4 2024; proof-of-concept results expected H1 2025.
Completed $11.8M private placement ($2.50/share, ~10% premium) in June 2024; net proceeds $11.7M.
Cash, cash equivalents and investments $54.1M as of June 30, 2024; working capital $51.9M.
R&D expenses $3.9M for Q2 2024 (up from $2.5M Q2 2023); net cash used in operations $11.2M H1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.